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ABSTRACT
Aims/Introduction: This study determined the prevalence and risk factors for diabetic
peripheral neuropathy (DPN) and painful DPN (pDPN) in patients with type 2 diabetes in
primary healthcare (PHC) and secondary healthcare (SHC) in Qatar.
Materials and Methods: This was a cross-sectional multicenter study. Adults with
type 2 diabetes were randomly enrolled from four PHC centers and two diabetes centers
in SHC in Qatar. Participants underwent assessment of clinical and metabolic parameters,
DPN and pDPN.
Results: A total of 1,386 individuals with type 2 diabetes (297 from PHC and 1,089 from
SHC) were recruited. The prevalence of DPN (14.8% vs 23.9%, P = 0.001) and pDPN
(18.1% vs 37.5%, P < 0.0001) was significantly lower in PHC compared with SHC, whereas
those with DPN at high risk for diabetic foot ulceration (31.8% vs 40.0%, P = 0.3) was
comparable. The prevalence of undiagnosed DPN (79.5% vs 82.3%, P = 0.66) was compa-
rably high, but undiagnosed pDPN (24.1% vs 71.5%, P < 0.0001) was lower in PHC com-
pared with SHC. The odds of DPN and pDPN increased with age and diabetes duration,
and DPN increased with poor glycemic control, hyperlipidemia and hypertension, whereas
pDPN increased with obesity and reduced physical activity.
Conclusions: The prevalence of DPN and pDPN in type 2 diabetes is lower in PHC
compared with SHC, and is attributed to overall better control of risk factors and referral
bias due to patients with poorly managed complications being referred to SHC. However,
approximately 80% of patients had not been previously diagnosed with DPN in PHC and
SHC. Furthermore, we identified a number of modifiable risk factors for PDN and pDPN.
INTRODUCTION
Diabetic peripheral neuropathy (DPN) is the most common
complication of diabetes and yet often remains undiagnosed1.
Late diagnosis can lead to significant morbidity in the form of
painful DPN (pDPN)2, erectile dysfunction3, diabetic foot ulcer-
ation (DFU)4 and amputation5, as well as increased mortality6.
Early diagnosis and management of DPN might limit or
reduce disease progression1. However, screening for DPN and
pDPN is inadequate7–9. The prevalence of DPN and pDPN
have been shown to range from 2.4 to 24.1%10,11 and 16 to
19%12,13 in primary care, and 32.114 and 21.0%15 in secondary
care in patients with type 2 diabetes, respectively. This wide
range has been attributed to differing populations and methods
used to identify DPN and pDPN. We have recently reported
that approximately 80% of patients with DPN9 and pDPN2
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have not previously been diagnosed in hospital clinics in sec-
ondary health care (SHC) in Qatar, which might lead to late
presentation with DFU. Indeed, in Qatar it has been reported
that 25% of patients with diabetes in SHC have foot prob-
lems16. This has serious consequences given that one in four
patients with DFU is at risk of amputation5, and the 5-year
mortality of people with a DFU is higher than many common
cancers17. Currently, the American Diabetes Association recom-
mends annual screening of DPN at diagnosis of type 2 diabetes
and 5 years after the diagnosis of type 1 diabetes by neurologi-
cal examination or monofilament testing, but there is no speci-
fic recommendation for pDPN1.
There are currently no US Food and Drug Adminis-
tration (FDA) approved therapies for DPN6. Lifestyle
interventions, including physical activity18 and avoidance
of smoking19,20 are advised, and optimization of glycemic
control19,21, treatment of hypertension22,23 and hyperlipi-
demia20,24 might improve DPN. FDA approved medica-
tions for treating painful symptoms include duloxetine,
pregabalin and tapentadol25.
According to the International Diabetes Federation, the
prevalence of diabetes in adults aged 20–79 years in Qatar
was 15.5% in 202026, which is almost twofold greater than
the 2019 reported prevalence of 8.3% in the rest of the
world27. Given the high prevalence of diabetes, in 2015 Qatar
launched the National Diabetes Strategy to improve the man-
agement of people with diabetes and its complications by
establishing common clinical care pathways within and
between primary healthcare (PHC) and SHC. We have,
therefore, applied the same methods and diagnostic criteria
in patients with type 2 diabetes to establish the prevalence
and risk factors for DPN and pDPN in PHC and SHC. We
believe the findings of the present study will be key to plan-
ning strategies to enable earlier diagnosis and optimal man-
agement of the often forgotten complication of diabetic
neuropathy in Qatar and the region.
METHODS
This was a cross-sectional, multicenter study. Individuals aged
18–85 years with type 2 diabetes mellitus were enrolled from
four PHC centers (Umm Ghuwailina, Al Khor, Al Daayen and
Al Rayyan) and the only two National Diabetes centers in
Qatar (Hamad General Hospital and Al-Wakra Hospital). Par-
ticipants were randomly enrolled and screened for eligibility on
the day they attended the clinic for their diabetes review
between June 2017 and February 2019. Exclusion criteria
included type 1 diabetes and other causes of neuropathy,
including severe vitamin B12 deficiency, chronic hypothyroidism
and chemotherapy.
The present study was approved by the institutional review
board of Weill Cornell Medicine-Qatar and Hamad Medical
Corporation. All participants gave informed consent to take
part in the study. The research adhered to the tenets of the
declaration of Helsinki.
Demographic and metabolic measures
Sex, ethnicity, age, duration of diabetes and body mass index
were recorded. The average systolic and diastolic blood pressure
of two readings were obtained from the participant’s left arm
while seated with the arm at heart level, using a standard zero
mercury sphygmomanometer after 10–15 min of rest. A non-
fasting blood sample was collected through venepuncture from
each participant into ethylenediaminetetraacetic acid tubes and
transported within 2 h to a central certified laboratory at
Hamad General Hospital. Glycated hemoglobin, total choles-
terol and triglyceride were measured by an autoanalyzer (Hita-
chi 747 autoanalyzer; Tokyo, Japan). Poor glycemic control was
defined as glycated hemoglobin ≥9%. Hypertension was defined
according to either an average systolic blood pressure
≥140 mmHg and/or the use of antihypertensive medication, as
described in the World Health Organization/International Soci-
ety of Hypertension guidelines28. Hyperlipidemia was defined
according to a total cholesterol level ≥6.2 mmol/L and/or
triglyceride level of ≥2.3 mmol/L or if the patient was treated
with a statin. Obesity was classified according to World Health
Organization criteria with a body mass index ≥30 kg/m229.
Current cigarette smoking was defined as having smoked at
least one cigarette every day for ≥1 year preceding the study
visit. Physical activity was defined as doing some physical activ-
ity, including walking for ≥30 min/day, at least three times a
week over the past year.
Assessment of diabetic neuropathy and painful neuropathy
The diagnosis of DPN was based on the presence of one or
more neuropathic symptoms and impaired vibration perception
threshold (VPT) in the feet. Subjective neurological symptoms,
such as burning pain, painful cold, electric shocks, tingling, pins
and needles, and numbness, were acquired through a face-to-
face interview with the investigators. VPT was measured by a
Horwell neurothesiometer (Scientific Laboratory Supplies, Not-
tingham, UK) on the pulp of the large toe on both feet, and
the average value of three measurements was recorded in volts
(V) ranging from 0 to 50 V. A VPT ≥15 V was defined as
impaired vibration perception consistent with the presence of
DPN30 and a VPT ≥25 V as high risk for DFU31.
Painful DPN was assessed using the Douleur Neuropathique
en 4 (DN4) questionnaire in Arabic and English, as previously
described32. The DN4 questionnaire has been validated for its
ability to distinguish neuropathic pain from non-neuropathic
pain33 and in the Arabic version34, and for pDPN32. It consists
of 10 questions: seven questions relating to the pain description
(burning, painful cold, electric shocks) and associated abnormal
sensations (tingling, pins and needles, numbness, itching), and
the other three neurological examination outcomes in the pain-
ful area for hypoesthesia to touch and pin prick using dispos-
able examination pins and allodynia to brushing. The scoring is
based on a yes (1 point) or no (0 point) answer, and each
question is equally weighted. A score ≥4 has a high sensitivity
(80%) and specificity (92%) for pDPN32. The questionnaire was
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administered by the investigator in either English or Arabic.
Previously diagnosed pDPN was self-reported. Medications for
pDPN were recorded.
All investigators underwent a formal training session on the
use and interpretation of the neurothesiometer and DN4 ques-
tionnaire.
Statistical analysis
The prevalence of DPN and pDPN across different demograph-
ics and risk factors as categorical variables were summarized
using frequency distributions. Variables in patients with DPN
or pDPN were compared between PHC and SHC using the
v2-test.
Binary logistic regression analysis was carried out with age,
duration of diabetes, sex, poor glycemic control, obesity, hyper-
lipidemia, hypertension, physical activity, smoking, ethnicity
and healthcare as independent variables, and DPN or pDPN as
the dependent variable. The multiple logistic regression model
included all variables with a P-value of ≤0.05 at the bivariate
level. Adjusted odds ratios, their corresponding 95% confidence
intervals and P-value are presented.
All analyses were carried out using IBM SPSS (version 26;
SPSS Inc., Armonk, NY, USA). A two-tailed P-value of ≤0.05
was considered significant.
RESULTS
Prevalence of DPN and pDPN in PHC compared with SHC
A total of 1,386 individuals with type 2 diabetes were recruited
from PHC (n = 297) and SHC (n = 1,089; Figure 1; Table 1).
The prevalence of DPN (14.8% vs 23.9%, P = 0.001) was sig-
nificantly lower in PHC compared with SHC. The percentage
of patients undiagnosed with DPN was comparable (79.5% vs
82.3%, P = 0.66) between PHC and SHC. The prevalence of
pDPN (18.1% vs 37.5%, P < 0.0001) and percentage of patients
undiagnosed with pDPN (24.1% vs 71.5%, P < 0.0001) was sig-
nificantly lower in PHC compared with SHC. The mean VPT
(10.4 – 7.2 V vs 12.5 – 9.4 V, P < 0.0001), DN4 score
(1.0 – 1.6 vs 2.5 – 2.6, P < 0.0001) and percentage of patients
with all neuropathic symptoms including burning, painful cold,
electric shocks, tingling, pins and needles, numbness, and itch-
ing were significantly lower in PHC compared with SHC
(Table 2). Although no patients in PHC had DFU, 6.2% had
DFU in SHC. However, the prevalence of those at high risk for
DFU was comparable (31.8% vs 40.0%, P = 0.3) between PHC
and SHC.
Risk factor management in PHC compared with SHC
More patients with type 2 diabetes aged >60 years (30.5% vs
23.2%, P = 0.001) and fewer patients aged 20–50 years (29.8%
vs 41.5%, P = 0.001) were under the care of PHC compared
with SHC. The body mass index (29.8 kg/m2 vs 31.5 kg/m2,
P = 0.0003) and percentage of patients with obesity (40.8% vs
53.3%, P = 0.001) was significantly lower in PHC compared
with SHC. Glycated hemoglobin was comparable, but the
percentage of patients with poor glycemic control (36.8% vs
44.0%, P = 0.04) was lower in PHC compared with SHC. In
PHC, the total cholesterol (3.9 mmol/L vs 4.4 mmol/L,
P < 0.0001) was lower and triglycerides were comparable com-
pared with SHC. However, hyperlipidemia was present in a sig-
nificantly lower percentage of patients in SHC compared with
PHC (73.2% vs 80.3%, P = 0.02). The systolic and diastolic
blood pressure, and percentage of patients with hypertension
was comparable between PHC and SHC. More patients under-
took physical activity (57.5% vs 38.2%, P < 0.0001), and fewer
patients smoked cigarettes (9.9% vs 17.3%, P = 0.003) in PHC
compared with SHC.
Association of risk factors for DPN in PHC and SHC
The odds of developing DPN increased by 2.4-fold in patients
aged 51–60 years (P < 0.0001), and 2.9-fold in those aged
>60 years compared with patients aged 20–50 years
(P < 0.0001; Table 3). The odds increased 2.2-fold with 11–
20 years of diabetes (P < 0.0001), to 3.9-fold with >20 years
of diabetes (P < 0.0001) compared with ≤10 years of diabetes.
The odds for DPN was 1.4-fold greater in men (P = 0.02).
The odds increased 1.5-fold in those with poor glycemic con-
trol (P = 0.02), and 1.6-fold in patients treated with insulin
and other antidiabetic therapy compared with patients treated
with metformin and other antidiabetic therapy (P = 0.006).
The odds increased 1.8-fold in those with hyperlipidemia
(P = 0.006), and 1.5-fold in those with hypertension
(P = 0.05). The association with obesity and ethnicity for
DPN was lost after controlling for risk factors. However, even
after adjusting for all risk factors, the odds of developing
DPN in SHC remained 2.1-fold higher than in PHC
(P = 0.001).
Association of risk factors for pDPN in PHC and SHC
The odds of developing pDPN was 1.5-fold greater in patients
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Figure 1 | Prevalence of diabetic peripheral neuropathy (DPN), painful
diabetic neuropathy (pDPN), undiagnosed DPN and pDPN in type 2
diabetes in primary and secondary healthcare. NS, not significant.
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50 years (P < 0.0001; Table 4). The odds increased from 2.2-
fold with 11–20 years of diabetes (P < 0.0001) to 4.4-fold with
>20 years of diabetes (P < 0.0001) compared with ≤10 years of
diabetes. The odds also increased by 1.7-fold in participants
treated with insulin/plus other antidiabetic therapy compared
with those treated with metformin/plus other antidiabetic ther-
apy (P < 0.0001). The odds increased 1.6-fold with obesity
(P = 0.002), and 1.4-fold in Arab participants compared with
South Asian participants (P = 0.03). However, the odds
decreased by 1.7-fold with physical activity (P = 0.01). The
association of poor glycemic control, hyperlipidemia, hyperten-
sion and sex with pDPN was lost after controlling for these risk
factors. However, even after adjusting for all risk factors, the
odds of developing pDPN in SHC was 2.4-fold higher than in
PHC (P < 0.0001).
DISCUSSION
The present study shows that the prevalence of DPN is 1.6-fold
lower and pDPN is twofold lower in PHC compared with
SHC. Furthermore, the percentage of patients with undiagnosed
DPN (~80%) and those at risk of DFU (32–40%) was extre-
mely high, and comparable between PHC and SHC, despite the
introduction of national diabetes care pathways. DPN was asso-
ciated with poor glycemic control, hyperlipidemia and hyper-
tension, whereas pDPN was associated with obesity, and was
lower in patients undertaking physical activity at least 3 days
per week. The higher prevalence of DPN and pDPN in SHC
remained significant, even after controlling for risk factors. This
might partly be attributed to referral bias, with more patients
with poorer control of risk factors and diabetic complication
being referred to SHC.
Table 1 | Prevalence of diabetic peripheral neuropathy, painful diabetic neuropathy, undiagnosed diabetic peripheral neuropathy and painful
diabetic neuropathy, and those at high risk of diabetic foot ulceration and their risk factors in type 2 diabetes in primary and secondary healthcare
Primary health care Secondary health care P-value
PHC vs SHC
Diabetic peripheral neuropathy 44/297 14.8% 260/1,089 23.9% 0.001
High risk for diabetic foot ulceration 14/44 31.8% 104/260 40.0% 0.30
Diabetic foot ulcer 0/44 0.0% 16/260 6.2% 0.13
Painful diabetic neuropathy 54/298 18.1% 410/1,092 37.5% <0.0001
Undiagnosed cases
Undiagnosed diabetic peripheral neuropathy 35/44 79.5% 214/260 82.3% 0.66
Undiagnosed painful diabetic neuropathy 13/54 24.1% 293/410 71.5% <0.0001
Risk factors
Age
20–50 years 88/295 29.8%† 445/1,073 41.5%‡ 0.001
51–60 years 117/295 39.7%† 379/1,073 35.3%†
>60 years 90/295 30.5%† 249/1,073 23.2%‡
Duration of diabetes
≤10 years 204/296 68.9%† 690/1,080 63.9%† 0.26
11–20 years 73/296 24.7%† 303/1,080 28.1%†
>20 years 19/296 6.4%† 87/1,080 8.1%†
Lifestyle modifiable risk factors
Physical activity 158/275 57.5%† 326/854 38.2%‡ <0.0001
Smoking 27/274 9.9% 157/909 17.3% 0.003
Cardiovascular modifiable risk factors
Poor glycemic control 98/266 36.8%† 436/991 44.0%‡ 0.04
Hyperlipidemia 208/259 80.3%† 738/1,008 73.2%‡ 0.02
Hypertension 176/274 64.2%† 669/1,040 64.3%† 0.98
Obesity 87/213 40.8%† 510/957 53.3%‡ 0.001
Systolic blood pressure (mmHg) 131.7 – 15.5 132.5 – 18.0 0.42
Diastolic blood pressure (mmHg) 78.8 – 8.0 78.2 – 10.2 0.32
BMI (kg/m2) 29.8 – 5.4 31.5 – 7.4 0.0003
HbA1c (mmol/mol) 63.1 – 19.7 65.5 – 21.9 0.08
HbA1c (%) 7.9 – 1.8 8.1 – 2.0 0.08
Cholesterol (mmol/L) 3.9 – 1.0 4.4 – 1.2 <0.0001
Triglyceride (mmol/L) 1.8 – 1.0 1.8 – 1.2 0.96
Variables were summarized using means and standard deviations for numeric variables, and frequency distribution for categorical variables. Contin-
ues and categorical variables were compared using unpaired t-test and v2-test, respectively. †,‡Rows with the same symbols are not statistically sig-
nificant, and different symbols are significantly different. BMI, body mass index; HbA1c, glycated hemoglobin; PHC, primary healthcare; SHC,
secondary healthcare.
4 J Diabetes Investig Vol.  No.   2020 ª 2020 The Authors. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd
O R I G I N A L A R T I C L E
Ponirakis et al. http://wileyonlinelibrary.com/journal/jdi
The DN4 questionnaire was chosen to define pDPN for
three reasons: (i) its diagnostic ability to distinguish neuropathic
pain from non-neuropathic pain, including osteoarthritis,
inflammation and mechanical low back pain (common differ-
entials, especially in PHC) for which it has been validated with
86% sensitivity and 83% specificity33; (ii) its diagnostic ability
specifically for pDPN with 80% sensitivity and 92% speci-
ficity32, and (iii) validation using the Arabic version showing
88% sensitivity and 75% specificity34. The higher prevalence of
Table 2 | Mean vibration perception threshold, Douleur Neuropathique en 4 questionnaire score, and percentage of neuropathic symptoms in
type 2 diabetes in primary and secondary healthcare
PHC SHC P-value
PHC vs SHC
Vibration perception threshold (V) 10.4 – 7.2 12.5 – 9.4 <0.0001
DN4 score 1.0 – 1.6 2.5 – 2.6 <0.0001
Burning pain (%) 22.6 46.7 <0.0001
Painful cold (%) 7.7 26.5 <0.0001
Electric shocks (%) 5.1 22.3 <0.0001
Tingling (%) 20.2 32.0 <0.0001
Pins and needles (%) 16.2 35.1 <0.0001
Numbness (%) 12.5 42.0 <0.0001
Itching (%) 7.8 16.7 <0.0001
Variables were summarized using means and standard deviations for numeric variables and frequency distribution for categorical variables. Contin-
ues and categorical variables were compared using unpaired t-test and x2, respectively. DN4, Douleur Neuropathique en 4 questionnaire; PHC, pri-
mary healthcare; SHC, secondary healthcare.
Table 3 | Predictors for diabetic peripheral neuropathy in primary and
secondary healthcare
Diabetic peripheral neuropathy AOR 95% CI P-value
Sex
Male 1
Female 0.7 0.5–0.9 0.02
Ethnic groups
Arabs 1
South Asians 0.8 0.5–1.1 0.19
Age
20–50 years 1
51–60 years 2.4 1.6–3.5 <0.0001
>60 years 2.9 1.9–4.5 <0.0001
Duration of diabetes
≤10 years 1
11–20 years 2.2 1.6–3.0 <0.0001
>20 years 3.9 2.4–6.4 <0.0001
Poor glycemic control 1.5 1.1–2.0 0.02
Hyperlipidemia 1.8 1.2–2.8 0.006
Hypertension 1.5 1.0–2.2 0.05
Obesity 1.3 0.9–1.8 0.20
Antidiabetic therapy
Metformin/plus 1
Insulin/plus 1.6 1.2–2.3 0.006
Primary healthcare 1
Secondary healthcare 2.1 1.4–3.2 0.001
The multiple logistic regression model included all variables with P-val-
ues of ≤0.05 at the bivariate level. Adjusted odds ratios (AOR), their cor-
responding 95% confidence intervals (CI) and P-value are presented.
Table 4 | Predictors for diabetic painful neuropathy in primary and
secondary healthcare
Painful neuropathy AOR 95% CI P-value
Sex
Male 1
Female 1.2 0.9–1.6 0.32
Ethnic groups
Arabs 1
South Asians 0.7 0.5–1.0 0.03
Age
20–50 years 1
51–60 years 1.5 1.1–2.0 0.02
>60 years 1.5 1.1–2.2 0.02
Duration of diabetes
≤10 years 1
11–20 years 2.2 1.6–3.0 <0.0001
>20 years 4.4 2.7–7.1 <0.0001
Poor glycemic control 1.2 0.9–1.6 0.2
Hyperlipidemia 1.1 0.8–1.5 0.58
Hypertension 1.3 0.9–1.8 0.13
Obesity 1.6 1.2–2.2 0.002
Physical activity 0.6 0.4–0.9 0.01
Antidiabetic therapy
Metformin/plus other therapy 1
Insulin/plus 1.7 1.3–2.4 <0.0001
Primary healthcare 1
Secondary healthcare 2.4 1.6–3.5 <0.0001
The multiple logistic regression model included all variables with P-
value of ≤0.05 at the bivariate level. Adjusted odds ratios (AOR), their
corresponding 95% confidence intervals (CI) and P-value are presented.
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pDPN compared with DPN might be attributed to the criteria
used to define these conditions. pDPN was defined according
to DN4, whereas DPN was based on symptoms and an ele-
vated VPT (>15 V).
There are currently no FDA approved therapies for DPN6.
However, screening annually for symptoms and signs of DPN
starting at diagnosis of type 2 diabetes is advocated on the basis
that early management of risk factors for DPN might reduce
the rate of disease progression, and treatment to relieve neuro-
pathic symptoms might improve the patient’s quality of life1.
We have recently assessed the prevalence of DPN and pDPN
in SHC in Qatar2,9. This is the first study to compare the
prevalence of DPN and pDPN in PHC and SHC using the
same criteria and in the same population. The prevalence of
DPN in both PHC and SHC in Qatar is lower compared with
the prevalence in SHC in other countries; for example, 37% in
Bahrain19, 60% in Turkey21, 49% in Iran35, 45% in the USA36,
32% in the UK14, 31% in Italy37 and 62% in China38. The
prevalence of pDPN is also lower in both SHC and PHC in
Qatar compared with studies from SHC, with a reported preva-
lence of 65% in Saudi Arabia39, 61% in Egypt40, 58% in Jordan
and 54% in Lebanon.
Despite the introduction of national diabetes pathways in
Qatar, the present study confirms an alarmingly high preva-
lence of undiagnosed DPN in PHC and SHC2,9. It highlights
the considerable need to educate both patients and physicians
on DPN and pDPN41. This might explain why up to 25% of
patients with diabetes in SHC in Qatar have foot problems16.
Currently, DPN is not assessed systematically, even using the
10-g monofilament, which in itself identifies only those with
advanced neuropathy1. Given that one in four patients with
DFU are at risk of amputation5, the present study highlights
the need for the National Diabetes Strategy to implement
annual DPN screening in PHC and SHC. This should be car-
ried out using evidence-based screening tests to detect incipient
small fiber damage to detect sudomotor dysfunction using
Sudoscan42 or Neuropad43, or vibration perception using a neu-
rothesiometer44, or cold or warm perception thresholds using
NerveCheck45; as opposed to monofilament testing, which is
convenient, but only detects advanced large fiber neuropathy. A
common reason for the underdiagnosis of pDPN is that
patients with symptoms are often unaware that the pain is
related to DPN and do not report them to their physician13,46.
Questionnaire, such as the DN432, and Leeds Assessment of
Neuropathic Symptoms and Signs (LANSS) pain scale47, can be
used to screen for neuropathic pain, and the Neuropathic Pain
Scale (NPS)48, Neuropathic Pain Symptom Inventory (NPSI)49
and Diabetic Peripheral Neuropathic Pain Impact measure
(DPNPI)50 can characterize subgroups of neuropathic pain
patients who might benefit from specific therapies, as well as
monitor the impact of treatment51. Reassuringly, we show a
much lower prevalence of patients with undiagnosed pDPN in
PHC, which might reflect a more systematic approach to iden-
tify neuropathic symptoms as part of a general screen for
complications, as opposed to SHC, where there is no formal
screening unless the physician refers for further assessment.
The lack of an FDA approved therapy for DPN often creates
a negative attitude toward the need to diagnose early DPN52.
However, the present study has identified a range of modifiable
risk factors for DPN, including poor glycemic control19,21,
hypertension22,23 and hyperlipidemia20,24, and for pDPN,
including obesity40,53–55 and reduced physical activity56,57.
Although, intensive glycemic control is advocated, the data for
an impact on DPN in type 2 diabetes patients are limited58–60,
and other cardiovascular risk factors, such as hypertension,
hyperlipidemia and obesity, might play a more important role.
Indeed, treatment with angiotensin converting enzyme inhibi-
tors22,23, statins61,62 or glucagon-like peptide-1 receptor ago-
nists63–65 might have a beneficial effect on DPN.
A limitation of the present study was the relatively small
number of participants from PHC, thus limiting the generaliz-
ability of the findings. A further limitation was the cross-sec-
tional design of this study, which limited the predictive validity
of the observed associations between the various risk factors
with DPN and pDPN.
In conclusion, the present study identified a lower prevalence
of DPN and pDPN in PHC compared with SHC, which might
be attributed to better overall risk factor control in PHC and
referral bias due to patients who are poorly managed with
complications being referred to SHC. Alarmingly, an equally
high proportion (~80%) of patients with DPN were undiag-
nosed in both PHC and SHC, highlighting the need for the
National Diabetes Strategy to implement annual DPN screen-
ing. The identification of hyperglycemia, hyperlipidemia and
hypertension as modifiable risk factors for DPN, and obesity
and physical activity as modifiable risk factors of pDPN provide
a robust argument to establish protocols for the early diagnosis
and management of DPN and pDPN.
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